Keyphrases
Prostate Cancer
100%
RP-1
33%
Disease States
33%
High Risk
33%
Androgen Receptor
33%
Therapeutic Strategies
33%
Clinically Significant
16%
Metastatic Disease
16%
Metastatic Cancer
16%
Cancer Treatment
16%
Genomic Heterogeneity
16%
Androgen Receptor Antagonist
16%
DNA Damage
16%
Widespread Adoption
16%
Metastasis
16%
PARP Inhibitor (PARPi)
16%
Patient Management
16%
Therapeutic Target
16%
Tumor Growth
16%
Receptor-independent
16%
RP-3
16%
Prostate
16%
Genetic Context
16%
Lineage Plasticity
16%
Clinical Practice
16%
Risk-based Approach
16%
Memorial Sloan-Kettering Cancer Center
16%
Microenvironment
16%
Clinically Significant Cancer
16%
Genetic Pathways
16%
Cancer Research
16%
Localized Disease
16%
Tumor Protein p53 (TP53)
16%
Germ Cells
16%
Androgen Deprivation Therapy
16%
Prognostic Model
16%
Molecular Pathways
16%
Evolving Landscape
16%
Successful Development
16%
Disease Progression
16%
Response Rate
16%
Cancer Progression
16%
Clinical Spectrum
16%
Medicine and Dentistry
Prostate Cancer
100%
Diseases
50%
Metastatic Carcinoma
50%
Androgen Receptor
50%
Biological Marker
33%
Cancer
33%
Disease Exacerbation
16%
Tumor Progression
16%
Cancer Research
16%
Malignant Neoplasm
16%
Somatics
16%
Patient Care
16%
Prognostic Model
16%
Germ Cell
16%
DNA Damage
16%
Androgen Deprivation Therapy
16%
Cancer Growth
16%
PARP Inhibitor
16%
Localized Disease
16%
Cancer Therapy
16%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Diseases
66%
Androgen Receptor
50%
Biological Marker
33%
Malignant Neoplasm
16%
Tumor Growth
16%
Androgen
16%
Disease Exacerbation
16%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
16%
Cancer Growth
16%